July 2021

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

• Karen A. Gelmon,
• Peter A. Fasching,
• Fergus J. Couch,
• ...
• Graham Walker,
• Joyce O'Shaughnessy
• Collaborating Investigators

Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors

• Seodhna M. Lynch,
• Niamh M. Russell,
• Stephen Barron,
• ...
• Catherine M. Kelly,
• Darran P. O'Connor,
• William M. Gallagher

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials

• Jenny Furlanetto,
• Frederik Marmé,
• Sabine Seiler,
• ...
• Volkmar Müller,
• Valentina Nekljudova,
• Sibylle Loibl

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

• Joyce O'Shaughnessy,
• Susana Sousa,
• Josefina Cruz,
• ...
• Zuzana Machackova,
• Ljiljana Stamatovic
• for the PHranceSCa study group

Nose in malignant mesothelioma—Prediction of response to immune checkpoint inhibitor treatment

• Maria J. Disselhorst,
• Rianne de Vries,
• Josine Quispel-Janssen,
• Marguerite Wolf-Lansdorf,
• Peter J. Sterk,
• Paul Baas

Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

• Julien Hadoux,
• Christina Kanaan,
• Alice Durand,
• ...
• Michel Ducreux,
• Jean-Yves Scoazec,
• Eric Baudin

Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study

• Vincenza Conteduca,
• Daniel Wetterskog,
• Elena Castro,
• ...
• David Olmos,
• Gerhardt Attard,
• Ugo De Giorgi

Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study

• Maryam Soleimani,
• Kevin Zou,
• Katherine Sunderland,
• ...
• Muhammad Zulfiqar,
• Kim N. Chi,
• Daniel J. Khalaf

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

• Helen Gogas,
• Reinhard Dummer,
• Paolo A. Ascierto,
• ...
• Ashwin Gollerkeri,
• Caroline Robert,
• Keith T. Flaherty

Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases

• Anne Zaremba,
• Manuel Philip,
• Jessica C. Hassel,
• ...
• Susanne Horn,
• Dirk Schadendorf,
• Elisabeth Livingstone

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”

• Patrick Schöffski,
• Maud Toulmonde,
• Anna Estival,
• ...
• Laura De Meulemeester,
• Christine Olungu,
• Hans Gelderblom

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis

• Michael Saerens,
• Nele Brusselaers,
• Sylvie Rottey,
• Alexander Decruyenaere,
• David Creytens,
• Lore Lapeire

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15

• Michael P. MacManus,
• Daniel Roos,
• Peter O'Brien,
• ...
• Mathias Bressel,
• Stephen Lade,
• John F. Seymour

Rare use of patient-reported outcomes in childhood cancer clinical trials – a systematic review of clinical trial registries

• David Riedl,
• Maria Rothmund,
• Anne-Sophie Darlington,
• ...
• Roman Crazzolara,
• Teresa de Rojas
• On behalf of the EORTC Quality of Life Group

Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study

• L.M.E. van Erp,
• H. Maurice-Stam,
• L.C.M. Kremer,
• ...
• M. van Gorp,
• E. van Dulmen-den Broeder,
• M.A. Grootenhuis

European trends in breast cancer mortality, 1980–2017 and predictions to 2025

• Cezary Wojtyla,
• Paola Bertuccio,
• Andrzej Wojtyla,
• Carlo La Vecchia

Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036

• Claus Garbe,
• Ulrike Keim,
• Sara Gandini,
• ...
• Lukas Flatz,
• Ulrike Leiter,
• David Whiteman

The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018

• Jan M. van Rees,
• Marloes A.G. Elferink,
• Pieter J. Tanis,
• Johannes H.W. de Wilt,
• Jacobus W.A. Burger,
• Cornelis Verhoef

Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK

• Adrian Gheorghe,
• Camille Maringe,
• James Spice,
• ...
• Bernard Rachet,
• Richard Sullivan,
• Ajay Aggarwal

Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study

• Martin Salzmann,
• Georgi Tosev,
• Melanie Heck,
• ...
• Alexander H. Enk,
• Martin Hartmann,
• Jessica C. Hassel

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

• Michele Maio,
• Christian Blank,
• Andrea Necchi,
• ...
• R. Bryan Bell,
• Giampaolo Tortora,
• Alexander M.M. Eggermont

Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19

Clinical outcomes of SARS-CoV-2-infected cancer patients undergoing surgery

• Caifeng Zou,
• Yuting Huang,
• Yuchi Ma,
• Feng Yang,
• Deliang Fu